Physician profile
Taylor Beatty
NPI 1891170577
$187,601.04
in general payments reported to CMS, 2019-2025
30 companies · $62K in 2025
The $62K reported for 2025 was more than what 96% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,178 · 2020: $1,768 · 2021: $1,100 · 2022: $13K · 2023: $45K · 2024: $61K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $162K · Food and Beverage: $3,300 · Travel and Lodging: $1,502 · Gift: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $162,096.95 |
| Food and Beverage | $3,300.04 |
| Travel and Lodging | $1,501.54 |
| Gift | $522.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ctl Medical Corporation | $173,559.38 | 2022-2025 | Spinal, Raphael Pedicle Screw System |
| Stryker Corporation | $6,364.22 | 2019-2025 | Mako, T2 Alpha, Gamma |
| Medtronic, INC. | $1,653.11 | 2021-2024 | Unid_pass, Mazor X System, Rialto Si Fusion System |
| Xtant Medical INC | $1,246.71 | 2024 | |
| Life Spine, INC. | $1,157.35 | 2021-2023 | Prolift Micro, Prolift Lateral |
| Medical Device Business Services, INC. | $610.49 | 2019-2020 | |
| Coastal Medical Technologies LLC | $454.82 | 2023-2025 | |
| Depuy Synthes Sales INC. | $366.49 | 2019 | |
| Zimmer Biomet Holdings, INC. | $323.55 | 2019-2022 | |
| Boston Scientific Corporation | $284.43 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Arthrex, INC. | $204.95 | 2024 | |
| Medtronic USA, INC. | $199.84 | 2019-2020 | |
| Orthofix Medical, INC. | $198.11 | 2019-2025 | Cervical-Stim, Spinal-Stim |
| Globus Medical, INC. | $167.75 | 2024 | Excelsius Deformity |
| Alphatec Spine, INC | $155.55 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microport Orthopedics INC | $139.06 | 2019 | |
| Encore Medical, Lp | $92.69 | 2024 | Djo Surgical |
| Ossur Americas, INC. | $67.72 | 2024-2025 | Unloader One X, Miami J |
| Smith+Nephew, INC. | $57.01 | 2022-2023 | K-15 Pork |
| Innovation Technologies INC | $48.99 | 2025 | Irrisept |
| Breg, INC | $45.79 | 2023 | Breg Vpulse, Plasmaflow, Polarcarewave |
| Cerapedics INC. | $37.33 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Mvp Orthopedics INC | $26.57 | 2023 | |
| Solventum Corporation | $23.87 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Wright Medical Technology, INC. | $22.91 | 2019 | |
| Elevation Spine, INC. | $22.44 | 2025 | |
| Bioventus LLC | $20.46 | 2025 | Xcell |
| Kerecis Limited | $18.55 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Vertex Pharmaceuticals Incorporated | $16.19 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $14.71 | 2023 | Iovera, Zilretta, Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Beatty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.